Amyotrophic Lateral Sclerosis Treatment Market By Drugs (Riluzole, Edaravone, Others), By Type (Sporadic ALS, Familial ALS), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

Amyotrophic Lateral Sclerosis Treatment Market

Amyotrophic lateral sclerosis is a type of motor neuron disease that specifically affects the upper and lower motor neurons. Moreover, it is known as Lou Gehrig's disease, a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. The disease is characterized by the gradual degeneration and death of motor neurons, which are the nerve cells responsible for controlling voluntary muscle movement.    

Key factors driving the growth of the amyotrophic lateral sclerosis treatment market include increase in prevalence of amyotrophic lateral sclerosis, initiatives by government and non-government organizations, and increase in awareness about ALS. Increase in prevalence of amyotrophic lateral sclerosis is one of the key drivers of the amyotrophic lateral sclerosis (ALS) treatment market. ALS is a relatively rare disease, but its incidence is increasing worldwide, which drives demand for effective treatments. 

In addition, many government and non-government organizations around the world have worked toward the treatment and management of amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis is a growing research area that requires coordination across National Institute of Neurological Disorders and Stroke (NINDS) and National Institutes of Health (NIH), as well as with public and private stakeholders. Thus, a rise in government funding for ALS research and an increase in public awareness of the ALS disease are the factors that drive the market growth.    

Moreover, one of the driving factors for ALS treatment is the need to manage the various symptoms associated with the disease. Treatment can help to manage symptoms of ALS disease and improve quality of life for patients. Thus, the need to manage the various symptoms of ALS disease propel the market growth. 

Furthermore, rise in awareness about diagnosis of amyotrophic lateral sclerosis disease leading to a greater demand for drugs that can treat this disease. This drives the growth of the amyotrophic lateral sclerosis treatment market. In addition, significant advancements in the development of drugs to treat amyotrophic lateral sclerosis, including the approval of new treatments in recent years such as RELYVRIO (sodium phenylbutyrate and taurursodiol) drive the market growth.  

The market also offers growth opportunities to the key players in the market. Increase in R&D activities for ALS treatment has a significant impact on the growth of the amyotrophic lateral sclerosis treatment market.  The primary goal of R&D activities for amyotrophic lateral sclerosis is to develop new therapies that can effectively treat the disease. A greater demand for these treatments is expected as more therapies are developed and approved, which is further anticipated to drive the market growth. The products under clinical evaluation are estimated to provide lucrative opportunity for market growth 

The amyotrophic lateral sclerosis treatment market is segmented into drug, type, distribution channel, and region. On the basis of drug, the market is categorized into Riluzole, Edaravone, and others. On the basis of type, it is bifurcated into sporadic ALS and familial ALS. On the basis of distribution channel, it is divided into hospital pharmacies, online providers, and drug stores and retail pharmacies. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). 

The key players profiled in the study include Aquestive Therapeutics, Inc., Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Viatris Inc., Amylyx Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Otsuka Pharmaceutical Co., Ltd., Covis Pharma GmbH, ITALFARMACO S.p.A., and Alkem Laboratories Ltd. The players in the market have been actively engaged in the adoption various strategies such as product approval and product launch to remain competitive and gain advantage over the competitors in the market. For instance, in May 2022, Mitsubishi Tanabe Pharma America, Inc. announced the U.S. Food and Drug Administration (FDA) has approved RADICAVA ORS (edaravone), the oral form of edaravone, for the treatment of amyotrophic lateral sclerosis (ALS).   

Key Market Insights

By drug, the Riluzole segment was the largest revenue contributor to the market and is estimated to reach $672.63 million by 2032, with a highest CAGR of 5.7%. 

By type, the sporadic ALS segment dominated the global market. However, the familial ALS segment is expected to be the fastest-growing segment with a CAGR of 8.5% during the forecast period. 

Based on distribution channel, the drug stores and retail pharmacies segment was the largest revenue contributor to the market in 2022. However, the online providers segment is expected to be the fastest-growing segment with a CAGR of 5.7% during the forecast period.   

Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period. 

Overview

The amyotrophic lateral sclerosis treatment market valued for $662.25 million in 2022 and is estimated to reach $1,038.94 million by 2032, exhibiting a CAGR of 4.6% from 2023 to 2032.   

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. ALS causes these nerve cells to gradually break down and die, which results in the loss of muscle control and eventual paralysis. The symptoms of ALS typically begin with muscle weakness or stiffness, often in the hands or feet, and gradually spread to other parts of the body. Other symptoms include difficulty speaking, swallowing, or breathing, as well as muscle cramps and twitching. There is currently no cure for ALS, and treatment mainly focuses on managing symptoms and improving the quality of life for people with the disease.    

Some of the drugs that are commonly used to treat amyotrophic lateral sclerosis include Riluzole, Edaravone, and Sodium phenylbutyrate and taurursodio. Riluzole works by reducing the release of glutamate, a neurotransmitter that damage motor neurons and Edaravone is a free radical scavenger that works by reducing oxidative stress in the body, which damage the motor neurons.    

The major factors that drive the growth of the global amyotrophic lateral sclerosis treatment market include, increase in prevalence of amyotrophic lateral sclerosis, and rise in approval of new drugs and therapies for ALS. The incidence of ALS is expected to rise, as the global population ages, leading to a growth in demand for treatments and therapies that may help to manage the symptoms and slow the progression of the disease.    

Another market driver is the growth in awareness and understanding of ALS among healthcare professionals, patients, and caregivers. There is a greater understanding of the underlying mechanisms of ALS and potential targets for treatment with more research being done on the disease and advances in medical technology. This has led to the development of new therapies, such as gene therapies and stem cell treatments, which are expected to drive market growth during the forecast period.    

In addition, regulatory frameworks and reimbursement policies may also impact the market for ALS treatments. The approval of new drugs and therapies by regulatory bodies, such as the U.S. FDA, may drive market growth by providing patients with access to new and innovative treatments. For instance, increase in pipeline products such as Tofersen,  ANX005 and others for treating an amyotrophic lateral sclerosis which is anticipated to provide lucrative opportunities to the market players. Reimbursement policies that provide coverage for these treatments can also help to expand the market by making them more accessible and affordable for patients.    

 However, limited understanding of the disease, stringent regulatory process for approving new treatments for ALS, which can delay the availability of new therapies for patients and higher treatment may restrict the market growth.  

The amyotrophic lateral sclerosis treatment market is segmented into drug, type, distribution channel, and region. On the basis of drug, the market is categorized into Riluzole, Edaravone, and others. On the basis of type, the market is bifurcated into sporadic ALS and familial ALS. On the basis of distribution channel, the market is classified into hospital pharmacies, online providers, and drug stores & retail pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).   

Major key players that operate in the global amyotrophic lateral sclerosis treatment market are Aquestive Therapeutics, Inc., Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Viatris Inc., Amylyx Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation,  Otsuka Pharmaceutical Co., Ltd., Covis Pharma GmbH, ITALFARMACO S.p.A., and Alkem Laboratories Ltd. Key players operating in the market have adopted product approval, agreement, and product launch as their key strategies to expand their product portfolio. For instance, in January 2023, Amylyx Pharmaceuticals, Inc. announced it has entered into an exclusive license and distribution agreement with Neopharm in which Neopharm is expected to commercialize to regulatory review and approval of AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS) in Israel, Gaza, West Bank, and the Palestinian. 

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the amyotrophic lateral sclerosis treatment market analysis from 2022 to 2032 to identify the prevailing amyotrophic lateral sclerosis treatment market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the amyotrophic lateral sclerosis treatment market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global amyotrophic lateral sclerosis treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Viatris Inc

Scope of Amyotrophic Lateral Sclerosis Treatment Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Bargaining power of suppliers

3.3.2. Bargaining power of buyers

3.3.3. Threat of substitutes

3.3.4. Threat of new entrants

3.3.5. Intensity of rivalry

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Growth in awareness and understanding of ALS

3.4.1.2. Increase in prevalence of amyotrophic lateral sclerosis

3.4.1.3. Initiatives by government and non-government organizations

3.4.2. Restraints

3.4.2.1. Side effects of drugs

3.4.3. Opportunities

3.4.3.1. Increase in R&D activities

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Riluzole

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Edaravone

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Others

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Sporadic ALS

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Familial ALS

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospital Pharmacies

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Online Providers

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Drug Stores and Retail Pharmacies

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. Market size and forecast, by Drugs

7.2.3. Market size and forecast, by Type

7.2.4. Market size and forecast, by Distribution Channel

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Key market trends, growth factors and opportunities

7.2.5.1.2. Market size and forecast, by Drugs

7.2.5.1.3. Market size and forecast, by Type

7.2.5.1.4. Market size and forecast, by Distribution Channel

7.2.5.2. Canada

7.2.5.2.1. Key market trends, growth factors and opportunities

7.2.5.2.2. Market size and forecast, by Drugs

7.2.5.2.3. Market size and forecast, by Type

7.2.5.2.4. Market size and forecast, by Distribution Channel

7.2.5.3. Mexico

7.2.5.3.1. Key market trends, growth factors and opportunities

7.2.5.3.2. Market size and forecast, by Drugs

7.2.5.3.3. Market size and forecast, by Type

7.2.5.3.4. Market size and forecast, by Distribution Channel

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Market size and forecast, by Drugs

7.3.3. Market size and forecast, by Type

7.3.4. Market size and forecast, by Distribution Channel

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Key market trends, growth factors and opportunities

7.3.5.1.2. Market size and forecast, by Drugs

7.3.5.1.3. Market size and forecast, by Type

7.3.5.1.4. Market size and forecast, by Distribution Channel

7.3.5.2. France

7.3.5.2.1. Key market trends, growth factors and opportunities

7.3.5.2.2. Market size and forecast, by Drugs

7.3.5.2.3. Market size and forecast, by Type

7.3.5.2.4. Market size and forecast, by Distribution Channel

7.3.5.3. UK

7.3.5.3.1. Key market trends, growth factors and opportunities

7.3.5.3.2. Market size and forecast, by Drugs

7.3.5.3.3. Market size and forecast, by Type

7.3.5.3.4. Market size and forecast, by Distribution Channel

7.3.5.4. Italy

7.3.5.4.1. Key market trends, growth factors and opportunities

7.3.5.4.2. Market size and forecast, by Drugs

7.3.5.4.3. Market size and forecast, by Type

7.3.5.4.4. Market size and forecast, by Distribution Channel

7.3.5.5. Spain

7.3.5.5.1. Key market trends, growth factors and opportunities

7.3.5.5.2. Market size and forecast, by Drugs

7.3.5.5.3. Market size and forecast, by Type

7.3.5.5.4. Market size and forecast, by Distribution Channel

7.3.5.6. Rest of Europe

7.3.5.6.1. Key market trends, growth factors and opportunities

7.3.5.6.2. Market size and forecast, by Drugs

7.3.5.6.3. Market size and forecast, by Type

7.3.5.6.4. Market size and forecast, by Distribution Channel

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Market size and forecast, by Drugs

7.4.3. Market size and forecast, by Type

7.4.4. Market size and forecast, by Distribution Channel

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Key market trends, growth factors and opportunities

7.4.5.1.2. Market size and forecast, by Drugs

7.4.5.1.3. Market size and forecast, by Type

7.4.5.1.4. Market size and forecast, by Distribution Channel

7.4.5.2. China

7.4.5.2.1. Key market trends, growth factors and opportunities

7.4.5.2.2. Market size and forecast, by Drugs

7.4.5.2.3. Market size and forecast, by Type

7.4.5.2.4. Market size and forecast, by Distribution Channel

7.4.5.3. Australia

7.4.5.3.1. Key market trends, growth factors and opportunities

7.4.5.3.2. Market size and forecast, by Drugs

7.4.5.3.3. Market size and forecast, by Type

7.4.5.3.4. Market size and forecast, by Distribution Channel

7.4.5.4. India

7.4.5.4.1. Key market trends, growth factors and opportunities

7.4.5.4.2. Market size and forecast, by Drugs

7.4.5.4.3. Market size and forecast, by Type

7.4.5.4.4. Market size and forecast, by Distribution Channel

7.4.5.5. South Korea

7.4.5.5.1. Key market trends, growth factors and opportunities

7.4.5.5.2. Market size and forecast, by Drugs

7.4.5.5.3. Market size and forecast, by Type

7.4.5.5.4. Market size and forecast, by Distribution Channel

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Key market trends, growth factors and opportunities

7.4.5.6.2. Market size and forecast, by Drugs

7.4.5.6.3. Market size and forecast, by Type

7.4.5.6.4. Market size and forecast, by Distribution Channel

7.5. LAMEA

7.5.1. Key trends and opportunities

7.5.2. Market size and forecast, by Drugs

7.5.3. Market size and forecast, by Type

7.5.4. Market size and forecast, by Distribution Channel

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Key market trends, growth factors and opportunities

7.5.5.1.2. Market size and forecast, by Drugs

7.5.5.1.3. Market size and forecast, by Type

7.5.5.1.4. Market size and forecast, by Distribution Channel

7.5.5.2. Saudi Arabia

7.5.5.2.1. Key market trends, growth factors and opportunities

7.5.5.2.2. Market size and forecast, by Drugs

7.5.5.2.3. Market size and forecast, by Type

7.5.5.2.4. Market size and forecast, by Distribution Channel

7.5.5.3. South Africa

7.5.5.3.1. Key market trends, growth factors and opportunities

7.5.5.3.2. Market size and forecast, by Drugs

7.5.5.3.3. Market size and forecast, by Type

7.5.5.3.4. Market size and forecast, by Distribution Channel

7.5.5.4. Rest of LAMEA

7.5.5.4.1. Key market trends, growth factors and opportunities

7.5.5.4.2. Market size and forecast, by Drugs

7.5.5.4.3. Market size and forecast, by Type

7.5.5.4.4. Market size and forecast, by Distribution Channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2022

9.1. Amylyx Pharmaceuticals, Inc.

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.1.7. Key strategic moves and developments

9.2. Aquestive Therapeutics, Inc.

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.3. Covis Pharma GmbH

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.4. Glenmark Pharmaceuticals Limited

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.5. ITALFARMACO S.p.A.

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.6. Mitsubishi Chemical Group Corporation

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.6.6. Business performance

9.6.7. Key strategic moves and developments

9.7. Sun Pharmaceutical Industries Ltd.

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.7.6. Business performance

9.8. Viatris Inc.

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.9. Alkem Laboratories Ltd

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.10. Otsuka Pharmaceutical Co., Ltd.

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfoli

LIST OF TABLES

TABLE 01. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 02. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR RILUZOLE, BY REGION, 2022-2032 ($MILLION)

TABLE 03. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR EDARAVONE, BY REGION, 2022-2032 ($MILLION)

TABLE 04. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 05. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 06. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR SPORADIC ALS, BY REGION, 2022-2032 ($MILLION)

TABLE 07. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR FAMILIAL ALS, BY REGION, 2022-2032 ($MILLION)

TABLE 08. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 09. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 10. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)

TABLE 11. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)

TABLE 12. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 13. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 14. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 15. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 16. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 17. U.S. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 18. U.S. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 19. U.S. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 20. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 21. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 22. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 23. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 24. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 25. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 26. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 27. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 28. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 29. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 30. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 31. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 32. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 33. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 34. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 35. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 36. UK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 37. UK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 38. UK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 39. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 40. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 41. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 42. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 43. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 44. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 45. REST OF EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 46. REST OF EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 47. REST OF EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 48. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 49. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 50. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 51. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 52. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 53. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 54. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 55. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 56. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 57. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 58. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 59. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 60. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 61. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 62. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 63. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 64. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 65. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 66. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 67. REST OF ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 68. REST OF ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 69. REST OF ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 70. LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 71. LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 72. LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 73. LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 74. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 75. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 76. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 77. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 78. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 79. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 80. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 81. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 82. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 83. REST OF LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)

TABLE 84. REST OF LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)

TABLE 85. REST OF LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)

TABLE 86. AMYLYX PHARMACEUTICALS, INC.: KEY EXECUTIVES

TABLE 87. AMYLYX PHARMACEUTICALS, INC.: COMPANY SNAPSHOT

TABLE 88. AMYLYX PHARMACEUTICALS, INC.: PRODUCT SEGMENTS

TABLE 89. AMYLYX PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO

TABLE 90. AMYLYX PHARMACEUTICALS, INC.: KEY STRATERGIES

TABLE 91. AQUESTIVE THERAPEUTICS, INC.: KEY EXECUTIVES

TABLE 92. AQUESTIVE THERAPEUTICS, INC.: COMPANY SNAPSHOT

TABLE 93. AQUESTIVE THERAPEUTICS, INC.: PRODUCT SEGMENTS

TABLE 94. AQUESTIVE THERAPEUTICS, INC.: PRODUCT PORTFOLIO

TABLE 95. COVIS PHARMA GMBH: KEY EXECUTIVES

TABLE 96. COVIS PHARMA GMBH: COMPANY SNAPSHOT

TABLE 97. COVIS PHARMA GMBH: PRODUCT SEGMENTS

TABLE 98. COVIS PHARMA GMBH: PRODUCT PORTFOLIO

TABLE 99. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES

TABLE 100. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT

TABLE 101. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS

TABLE 102. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO

TABLE 103. ITALFARMACO S.P.A.: KEY EXECUTIVES

TABLE 104. ITALFARMACO S.P.A.: COMPANY SNAPSHOT

TABLE 105. ITALFARMACO S.P.A.: PRODUCT SEGMENTS

TABLE 106. ITALFARMACO S.P.A.: PRODUCT PORTFOLIO

TABLE 107. MITSUBISHI CHEMICAL GROUP CORPORATION: KEY EXECUTIVES

TABLE 108. MITSUBISHI CHEMICAL GROUP CORPORATION: COMPANY SNAPSHOT

TABLE 109. MITSUBISHI CHEMICAL GROUP CORPORATION: PRODUCT SEGMENTS

TABLE 110. MITSUBISHI CHEMICAL GROUP CORPORATION: PRODUCT PORTFOLIO

TABLE 111. MITSUBISHI CHEMICAL GROUP CORPORATION: KEY STRATERGIES

TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES

TABLE 113. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

TABLE 114. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS

TABLE 115. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 116. VIATRIS INC.: KEY EXECUTIVES

TABLE 117. VIATRIS INC.: COMPANY SNAPSHOT

TABLE 118. VIATRIS INC.: PRODUCT SEGMENTS

TABLE 119. VIATRIS INC.: PRODUCT PORTFOLIO

TABLE 120. ALKEM LABORATORIES LTD: KEY EXECUTIVES

TABLE 121. ALKEM LABORATORIES LTD: COMPANY SNAPSHOT

TABLE 122. ALKEM LABORATORIES LTD: PRODUCT SEGMENTS

TABLE 123. ALKEM LABORATORIES LTD: PRODUCT PORTFOLIO

TABLE 124. OTSUKA PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES

TABLE 125. OTSUKA PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT

TABLE 126. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT SEGMENTS

TABLE 127. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO LIST OF FIGURES

FIGURE 01. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET (2023-2032)

FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 05. MODERATE BARGAINING POWER OF BUYERS

FIGURE 06. MODERATE THREAT OF SUBSTITUTES

FIGURE 07. MODERATE THREAT OF NEW ENTRANTS

FIGURE 08. MODERATE INTENSITY OF RIVALRY

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALAMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET

FIGURE 10. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR RILUZOLE, BY COUNTRY 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR EDARAVONE, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 14. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR SPORADIC ALS, BY COUNTRY 2022 AND 2032(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR FAMILIAL ALS, BY COUNTRY 2022 AND 2032(%)

FIGURE 17. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)

FIGURE 21. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET BY REGION, 2022

FIGURE 22. U.S. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 23. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 24. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 25. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 26. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 27. UK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 28. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 29. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 30. REST OF EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 31. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 32. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 33. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 34. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 35. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 36. REST OF ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 37. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 38. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 39. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 40. REST OF LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, 2022-2032 ($MILLION)

FIGURE 41. TOP WINNING STRATEGIES, BY YEAR

FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 45. COMPETITIVE DASHBOARD

FIGURE 46. COMPETITIVE HEATMAP: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET

FIGURE 47. TOP PLAYER POSITIONING, 2022

FIGURE 48. AMYLYX PHARMACEUTICALS, INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 49. AQUESTIVE THERAPEUTICS, INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 50. AQUESTIVE THERAPEUTICS, INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 51. GLENMARK PHARMACEUTICALS LIMITED: NET SALES, 2020-2022 ($MILLION)

FIGURE 52. GLENMARK PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 53. MITSUBISHI CHEMICAL GROUP CORPORATION: NET SALES, 2020-2022 ($MILLION)

FIGURE 54. MITSUBISHI CHEMICAL GROUP CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 55. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)

FIGURE 56. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)

FIGURE 57. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)

FIGURE 58. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 59. ALKEM LABORATORIES LTD.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 60. ALKEM LABORATORIES LTD.: REVENUE SHARE BY REGION, 2022 (%